Vincerx Pharma “announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and common stock warrants in the proposed offering will be offered by Vincerx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners is acting as the sole bookrunning manager for the offering.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VINC:
- Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
- Vincerx: progress for VIP236 and VIP943 for solid tumors presented at AACR
- Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- Is VINC a Buy, Before Earnings?